Writing for Human and AI Reviewers: The New Way to File

The rise of automated  FDA AI reviewers means mastering the balance between machine-readable data and clear medical storytelling. It is no longer optional—it is the key to avoiding costly filing delays.

By Michael Bronfman

May 11, 2026

The world of medicine is changing fast. For decades, pharmaceutical companies followed a simple path: run a study, write a report, and send it to the Food and Drug Administration (FDA). The “audience” was always a group of human scientists. But in 2026, the rules have shifted. Today, when a company submits a new drug application, the first “eyes” on the document might not be human at all.

Smart software and advanced data tools now help regulators look through thousands of pages in seconds. This means that if you are writing a regulatory submission, you are no longer just writing for a doctor or a chemist. You are writing for a machine, too. This double audience requires a whole new way of thinking about how we present science.

Why This Matters Now

The FDA recently released new rules about how companies can use smart technology in their filings. They made a big distinction between “low risk” and “high risk” uses. This matters because it tells companies where they need to be the most careful and spend the most time.

• High Risk: If a computer program is used to select which patients receive a drug, determine the dose, or identify safety signals, the FDA looks at it very closely. This is because these tasks directly impact whether a drug is safe for people. This is the area of high scrutiny.

• Low Risk: If the technology is just helping with internal office work, scheduling meetings, or organizing files, the requirements are much lighter.

Because of these new rules, companies have to change how they communicate. They have to be clearer and more organized than ever before. If a machine cannot understand your report, it might flag it as a mistake, even if the science is perfect. A flag from a machine can lead to months of delays, costing companies millions of dollars and keeping medicine away from patients who need it.

Writing for the Machine: What Does It Mean?

Machines do not read as we do. They do not look for beautiful prose or clever metaphors. They do not get impressed by fancy vocabulary. Instead, they look for patterns, data points, and absolute consistency. To get a submission through a machine review without any red flags, writers must use a front-loading strategy.

Front Loading Clarity

“Front loading” means putting the most important information at the very beginning of every section. Instead of building up to a conclusion like a mystery novel, you state the conclusion first.

• Old way: After reviewing 500 patients over 6 months and checking their blood pressure daily, we found that the drug worked.

• New way: The drug reduced blood pressure by 15% in 500 patients. This conclusion is based on a six-month study where…

This helps the machine categorize the information instantly. It creates a “map” for the software to follow.

Avoiding Inconsistencies

One of the biggest reasons a filing gets flagged today is a data mismatch. Imagine you say a drug is 90% effective on page 10, but a table on page 400 says 89.9%. A human might realize it is simply a matter of rounding up and continuing reading. A machine sees a red flag and stops.

To prevent this, companies are now doing AI readiness reviews. This is a step where the company runs its own software on the document before sending it to the government. They look for the same things the FDA’s machines will look for:

1. Terminology: Using the exact same word for a concept every single time. Do not call it “the medicine” in one spot and “the compound” in another if you want the machine to track it easily.

2. Cross References: Making sure every link to a chart or table actually works and points to the precise data.

3. Structure: Following the eCTD format (electronic Common Technical Document) perfectly, so the software knows where to look for information.

The Human Factor: Keeping the Science Real

Even though machines are doing the heavy lifting, humans still make the final decision. A doctor at the FDA still needs to trust that the drug works. This creates a double challenge. You have to be technical enough for a computer but clear enough for a person.

The Problem with “Robot Speak”

Sometimes, when people try to make things easy for computers, the writing becomes stiff and hard to follow. This is a mistake. If a human reviewer gets confused ot just bored, they may start to doubt the work. The best regulatory writing today uses plain language principles.

• Short Sentences: Long, winding sentences may confuse both people and software. Aim for 20 words or fewer.

• Active Voice: Saying “The study showed…” instead of “It was shown by the study…” makes the facts stand out and defines who is responsible for the action.

• Bullet Points: Lists are easy for machines to scan and for busy human reviewers to read quickly during a long workday.

High Scrutiny Areas: Where Accuracy Counts Most

The FDA Guidance for Industry focuses heavily on a few specific areas. If your submission uses advanced tech for these, expect the highest level of checking:

1. Patient Stratification

This is a fancy way of saying that patients are being sorted into groups. If a computer picks which patients will benefit most from a drug based on their DNA or history, the FDA wants to know exactly why. You cannot just say “the computer said so.” You have to explain the logic in a way a human can verify.

2. Dose Optimization

Finding the right amount of medicine to give someone is a science. If you use a machine to find that “perfect dose,” you must prove the machine isn’t making a mistake that could hurt someone. This requires showing the “math” behind the machine’s decision.

3. Real World Data Analysis

Sometimes companies analyze health records from millions of people to see how a drug works in the real world. This is a mountain of data. Machines are great at this, but they can also find patterns that don’t actually exist (called “noise”). Your report must explain how you ensured the data was clean and the patterns were genuine.

4. Safety Signal Detection

This is about finding side effects. If a machine is the first thing to “notice” a side effect in a clinical trial, the documentation must show how that information was passed to human doctors for a final check. The human must always be in the loop.

The Importance of Pre-Submission Checks

In the old days, a team would proofread a document for typos and then send it off. In 2026, that is not enough. The “Internal AI Readiness Review” is now a required step for any serious pharma company.

This process involves using tools to “stress test” the document. For example, the team asks:

• “Can a computer find the primary endpoint in less than one second?”

• “Are there any hidden characters or weird formatting that will break the FDA’s software?”

According to Clinical Leader experts, companies that skip this step often face “Refusal to File” letters. This means the FDA will not even look at the science because the document itself is too messy for their tools to handle.

The Role of the Medical Writer in 2026

The job of a medical writer has changed. It is no longer just about writing; it is about information architecture. A writer today must understand how data flows from the lab into a table and convey that with a paragraph.

They act as a bridge. On one side, they have the data scientists who talk in code and numbers. On the other side, they have the regulators who want to ensure public safety. The writer must translate complex data into a structured format that satisfies both software scanners and human doctors. This requires a deep understanding of the eCTD structure and the ability to write with mathematical precision.

How to Prepare: A Practical Checklist

If you are working on a pharma team, you cannot wait until the last minute to think about these things. Preparation starts months before the “submit” button is pushed.

Ethics and Transparency: The “Explainable” Requirement

One thing a machine cannot do is be ethical. It cannot think about the spirit of the law or the “heart” of a patient. That is why transparency is the biggest buzzword in 2026.

When you use a machine to help write or analyze a filing, you must be honest about it. You must show the pathway the machine followed to reach its answer. This is often called Explainable AI. If a regulator can see the steps, they can trust the result. If the process is obscured, a “black box” in which no one knows how the answer was derived, the FDA will likely reject it.

Bridging the Gap

Writing for both human and machine reviewers is a new skill, but it is one that every professional in the pharmaceutical industry needs to learn. By focusing on structure, consistency, and clear language, companies can get life-saving drugs to patients faster.

The goal should not be to let the machines take over the process. Instead, the goal is to use the machines to make our work more accurate and organized. This allows FDA staff to spend less time looking for errors and more time examining the science. When we write for both audiences, everyone wins—especially the patients waiting for new treatments.

For more information on the technical side of these filings and to stay updated on new research, you can explore the Wiley Online Library.

Key Takeaways for understanding

• Machines are now helping regulators read drug reports. Because of this, we have to write in a way that doesn’t confuse the software.

• Consistency is king. If you use different words for the same thing or have small math errors, the machine will flag it as a big problem.

• The FDA cares most about “High Risk” tasks. If a computer is used to determine a patient’s dose or identify safety issues, the rules are much stricter.

• Clear writing helps humans and computers. Short sentences, bullet points, and putting the main point first (front loading) make the report better for everyone.

• Always do a “practice run.” Companies now use their own software to check their reports for mistakes before sending them to the government.

Don’t let a technical red flag stand between your breakthrough and the patients who need it most. Contact Metis Consulting Services today to ensure your next submission is AI-ready, human-approved, and built for success.

How AI Is Reducing Drug Development Timelines From Years to Months

The traditional path to bringing life-saving medicine to market is a marathon that often spans over a decade. This week in the Guardrail, we explore how artificial intelligence is shattering these timelines, transforming a process that once took years into one that takes mere months

Written by Michael Bronfman for Metis Consulting Services

December 29, 2025

Developing new medicines has long been one of the slowest processes in science. In the traditional system, creating a new drug from the first idea to a product patients can use often takes ten to fifteen years, costs billions of dollars, and succeeds less than one in ten times. This long and expensive process leaves many patients waiting while the disease continues to cause suffering.

Today, artificial intelligence (AI) is changing this story. With the help of AI, scientists and companies are finding ways to shrink drug development timelines from years to months. Reshaping the pharmaceutical industry can accelerate drug development, improve efficiency, and potentially increase the success of projects.

In this article, we explain how AI is speeding up drug development, which stages of the process are changing most, and what this means for patients, scientists, and the future of medicine.

The Drug Development Timeline:

Before we explore AI, it is essential to understand the historical pathway of drug development. The process has multiple stages:

1. Target Identification: a molecule or biological process that is modifiable to treat a disease is identified by researchers.

2. Drug Discovery: Scientists design or find chemical compounds to interact with the target.

3. Preclinical Testing: To assess safety and efficacy, compounds are evaluated in cell and animal models.

4. Clinical Trials: If a compound is promising, it proceeds to human trials in three phases to assess safety and efficacy.

5. Regulatory Approval: Health authorities, such as the EMA and the FDA, review all data before approving a drug.

Each step can take years, especially clinical trials. Even after all this work, most drug candidates fail before approval. The combined effect is slow progress for patients and high costs for companies.

AI is now being used to transform nearly every stage of this timeline, thereby accelerating drug development and making it more predictable.

How AI Speeds Up Drug Development

1. Target Identification in Months Instead of Years

   Target identification was once a lengthy, manual process involving laboratory experiments and trial-and-error. AI now allows researchers to analyze millions of data points from genetics, proteomics, and clinical records in hours or days rather than years. Machine learning models can identify potential biological targets much more quickly¹.

   These advanced algorithms process data far faster than humans can and find connections that might be invisible in traditional research. Scientists can then decide which targets are worth pursuing months earlier than before, reducing the earliest phase of drug discovery from years to months².

2. AI Accelerates Lead Optimization

   Once researchers have a target, the next step is to find compounds that interact with that target effectively and safely. In the past, this involved testing thousands of molecules in the lab. Now, AI can simulate molecule interactions in a computer, significantly shrinking the time needed for lead optimization³.

   AI models can predict how changes to a molecule’s structure will affect its performance. These predictions reduce the amount of physical laboratory work required and help scientists focus on the most promising candidates first³. This step, which once took several years, can now be completed in a handful of months in some cases¹.

3. Predicting Outcomes Before Lab Tests Begin

   AI can also forecast how a potential drug might behave in real biological systems. This capability enables researchers to assess toxicity, absorption, metabolism, and possible side effects in advance².

   For example, deep AI models can now simulate aspects of human biology that once required years of animal testing or early human trials². These predictions help researchers avoid investing time in compounds likely to fail later. When AI rules out unworkable options early, it saves years of work and millions of dollars³.

4. Generative AI Is Designing Drug Candidates

   Generative AI is a subset of Artificial Intelligence designed to create new molecules. This technology can generate tens of thousands of potential drug structures within hours, narrowing them down to the most promising options⁴.

   Some of these AI-designed molecules are entering clinical trials much faster than traditional drug candidates. In one example, an AI platform developed a candidate and reached preclinical testing in 13 to 18 months, rather than the typical 2.5 to 4 years⁴.

5. Improving Success Rates in Early Trials

   Traditional methods often yield a high failure rate before human testing begins. However, AI-assisted drug candidates exhibit substantially higher success rates in early clinical phases than conventional compounds⁵.

   Industry studies report that AI-discovered candidates achieve Phase I success rates of 80–90%, compared with the industry average of 40–65%¹. These rates mean fewer setbacks and less time.

6. Faster Clinical Trial Design and Enrollment

   AI is transforming clinical trials, which are among the most protracted and most expensive phases of development. By analyzing patient data, AI can more quickly identify the most suitable participants for a study⁶, thereby accelerating enrollment and increasing the likelihood that trials will yield meaningful results.

   Other AI tools monitor patient data in real time and predict how participants may respond⁶. These tools can help researchers quickly adjust trial protocols, reducing months or even years from the clinical trial timeline⁶.

Real-World Examples of AI Cutting Timelines

AI Platforms Reducing Drug Development to Months

Some companies are already using AI to compress timelines dramatically. For example, a biotechnology firm developed a system that could shorten the stages of small-molecule drug development from months to two weeks for certain tasks⁷. That same system is projected to save one to one-and-a-half years before clinical trials start⁷.

Collaborations Between AI Firms and Big Pharma

Major pharmaceutical companies are partnering with AI startups to accelerate drug design. One collaboration between a U.S. biotech and a global pharmaceutical firm uses AI to produce drug candidates in three to four weeks from design to lab testing⁸.

These partnerships demonstrate that well-established pharmaceutical companies are adopting AI technologies to remain competitive and bring therapies to patients more quickly.

Why This Matters for Patients and Society

Faster drug development enables life-changing therapies to reach patients sooner. For patients with rare diseases or conditions for which there are no effective treatments, time saved in development is time saved from suffering. It also means that health systems could respond more rapidly to emerging disease threats, such as outbreaks or rising rates of chronic illness.

Accelerated development may reduce costs. When early failure is avoided and fewer resources are spent on unpromising candidates, resources are freed for investment in further research and development. These cost savings may eventually lower prices for patients, although this effect may depend on regulation and market forces.

Finally, increased efficiency may encourage greater investment in areas once considered too risky or too slow, such as treatments for neurological diseases or complex cancers.

Challenges and Realities

While AI is transforming drug development, we must remain grounded in reality. AI does not eliminate the need for human creativity, rigorous scientific validation, safety testing, or regulatory review. Human oversight remains essential in laboratory work, clinical trials, and data interpretation.

The future will involve proper regulation of AI tools to ensure they are safe, ethical, and transparent. But even with these limitations, the transformation AI brings is real and growing⁶.

Artificial intelligence is reshaping drug development in profound ways. From speeding target identification to optimizing molecules in silico, designing novel compounds with generative algorithms, and improving clinical trial outcomes, AI is making drug discovery faster, more innovative, and more efficient.

Instead of taking ten to fifteen years, new medicines are developed in a few years or even months. AI is not replacing scientists. Instead, it is amplifying their abilities, allowing them to focus on high-impact decisions while machines handle routine, data-intensive tasks. This partnership promises a future where better medicines reach patients sooner, with greater success, and at lower cost.

The era of AI-powered drug development has begun, and it will transform how medicines are developed for decades to come.  

Ready to accelerate your innovation? The future of pharmaceutical efficiency isn’t just about better data—it’s about better strategy. Discover how our expertise can help your organization lead the next generation of medical breakthroughs.  Contact us today hello@metisconsultingservices.com

Footnotes

1. All About AI – AI in Drug Development Statistics 2025
   https://www.allaboutai.com/resources/ai-statistics/drug-development/
   
   

2. World Health AI – Drug Discovery Accelerates Development
   https://www.worldhealth.ai/insights/drug-discovery
   
   

3. Simbo AI – The Future of Drug Discovery
   https://www.simbo.ai/blog/the-future-of-drug-discovery-how-ai-is-accelerating-development-timelines-and-improving-efficiency-in-pharmaceutical-research-467406/